Tolrestat

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tolrestat
Skeletal formula of tolrestat
Ball-and-stick model of the tolrestat molecule
Systematic (IUPAC) name
N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbothioyl}-N-methylglycine
Legal status
Legal status
  • Withdrawn from market
Identifiers
CAS Number 82964-04-3 YesY
ATC code A10XA01 (WHO)
PubChem CID 53359
IUPHAR/BPS 7404
UNII 0T93LG5NMK N
KEGG D02323 YesY
ChEMBL CHEMBL436 N
Chemical data
Formula C16H14F3NO3S
Molar mass 357.34 g/mol
 NYesY (what is this?)  (verify)

Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor[1] which was approved for the control of certain diabetic complications.[2]

While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase.

References[edit]

  1. ^ Sestanj K, Bellini F, Fung S, et al. (March 1984). "N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor". J. Med. Chem. 27 (3): 255–6. doi:10.1021/jm00369a003. PMID 6422042. 
  2. ^ Kador PF, Kinoshita JH, Sharpless NE (July 1985). "Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications". J. Med. Chem. 28 (7): 841–9. doi:10.1021/jm00145a001. PMID 3925146.